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Leukemia Therapy
Yimei Feng, Xinghua Chen,* Lei Gao
MicroRNAs have remained in the spotlight since
their discovery. More and more studies have shown
that miRNAs play important roles in pathologic
processes in solid tumors. Among them, micro-
RNA-21 (miR-21) is one of the most prominent
miRNAs implicated in the genesis and progression
of human cancer. Few studies, however, have fo-
cused on the mechanism of gene regulation by
miR-21 and its roles in hematopoiesis and leuke-
mogenesis. Because miR-21 is highly expressed in
leukemic cells, here we present a hypothesis that
knockdown of miR-21 may be a novel approach
for leukemia therapy. MiR-21 may also be a new
diagnostic marker and therapeutic target for 
leukemia.
MicroRNAs Regulate Hematopoiesis
MicroRNAs are a class of small (19–21 nucleotides)
non-coding RNA molecules that have important
roles in many cellular pathways and whose 
aberrant expression appears to be a common fea-
ture of malignancy.1 Hematopoiesis is sustained
by continuous differentiation of multipotent
hematopoietic stem cells into hematopoietic
progenitor cells, giving rise to different lineages and
mature blood cells. Accordingly, the hematopoi-
etic system becomes a good model for microRNA
research. Hematopoiesis is governed by the con-
comitant alteration in expression of several genes.
Given the ability of a single miRNA to control the
expression of several genes, it is proposed that
miRNAs regulate the process of hematopoiesis.2
MiR-21 Fingerprints During
Tumorigenesis, Including Leukemia
MiR-21 is one of the most prominent miRNAs
implicated in the genesis and progression of
human cancer.3 MiR-21 is known by a number of
synonyms including hsa-mir-21, MIR21, miR-21,
MIRN21 and miRNA21. In Homo sapiens, the
MIRN21 gene (DNA of premiR-21) is located on
chromosome 17q23.2 and is highly expressed in
different tumor types. MIRN21 has been involved
in promoting tumor growth, proliferation, anti-
apoptosis, migration and response to gemcitabine-
based chemotherapy. The potential targets of
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miR-21 include the programmed cell death protein
4, reversion-inducing cysteine-rich protein with
kazal motifs, tropomyosin 1, sprouty 2, phospha-
tase and tensin (PTEN) homolog and Nuclear
factor IB (NFIB). More in-depth functional stud-
ies with miR-21 are demonstrating that miR-21
displays oncogenic activities and can be classed
as an oncomir in solid tumors. In contrast, the
role of miR-21 in the proliferation and differenti-
ation of hematologic neoplasm cells has at-
tracted little attention.
Chronic lymphocytic leukemia (CLL) is the
most common leukemia among adults in Western
countries, and accounts for about 30% of all
leukemia patients.4 Currently, little is known re-
garding the pathogenic factors initiating and ag-
gravating this disease.
CLL patients have been characterized by sig-
nificant overexpression of miR-21. Expression 
of miR-21 in patients with CLL is dramatically
higher (up to 10-fold) than that in CD19+ lym-
phocytes of normal people.5 Overexpression of
miR-21 may, therefore, be one of the initiating
events occurring in CLL. Gazon et al found that
miR-21 was upregulated in acute myeloid
leukemia (AML) patients with t (6;11).6 Jongen-
Lavrencic et al reported that miR-21 is consistently
upregulated in AML, regardless of cytogenetic and
molecular subtype.7 Ectopically raising miR-21
expression in myeloma cells significantly re-
duced apoptosis levels. Loffler et al reasoned that
miR-21 might contribute to the Stat3-dependent
survival of myeloma cells.8 MiR-21, measured 
by quantitative RT-PCR (reverse transcription-
polymerase chain reaction), was also upregulated
in T-cell leukemic (T-ALL) and T-cell lymphoma
(ALCL) cell lines.9 There are two distinct molecu-
lar subtypes of diffuse large B cell lymphomas:
germinal center B cell-like and activated B cell-
like. Lawrie et al identified that miR-21 was more
highly expressed in activated B cell-like cell lines
compared with the germinal center B cell-like cell
lines.10 Moreover, through multivariate analysis,
the expression of miR-21 was shown to be an in-
dependent prognostic indicator in diffuse large B
cell lymphomas.10
Knockdown of MiR-21 as a Novel
Approach for Leukemia Therapy
We have raised a hypothesis that knockdown of
miR-21 in leukemic cells can suppress the occur-
rence and aggravation of leukemia. The main cause
of residual leukemia and recurrence of leukemia
is the existence of leukemic stem cells. Therefore,
a lentivirus vector of anti-miR-21 could be con-
structed and then transfected into leukemic stem
cells. In that way, after transfection with the anti-
miR-21 oligonucleotide, the expression of anti-
apoptotic protein Bcl-2 in leukemia cells in the
patient is decreased, while simultaneously tumor
suppressor levels, such as PTEN, tropomyosin 1
and programmed cell death protein 4, are in-
creased. Furthermore, the level of miR-21 could be
used as a diagnostic marker. More information
concerning the genesis, progression and progno-
sis of leukemia could be gathered by monitoring
the expression of miR-21.
Knockdown of MiR-21 Inhibits the
Development of Cancer Cells
Accumulating data is beginning to support the
attractive notion that sequence-specific inhibition
of a single oncomir, miR-21, can provide a novel
therapeutic approach to modulate deregulated
proteins in cancer. For example, knockdown of
miR-21 in cultured glioblastoma cells triggered
activation of caspases and lead to increased ap-
optotic cell death.11 Furthermore, knockdown of
miR-21 in metastatic breast cancer MDA-MB-231
cells significantly reduced invasion and lung
metastasis.12 Knockdown of miR-21 in breast
cancer MCF-7 cells also lead to suppression of
cell growth in vitro and tumor growth in a mouse
model.13 Additionally, knockdown of miR-21 in
hepatic cells increased expression of the PTEN
homolog tumor suppressor, and decreased tumor
cell proliferation, migration and invasion.14 In
short, these studies suggest that deletion or down-
regulation of miR-21 inhibits the development
of cancer cells, thus leading to interference with
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cancer initiation and progression. Given the pre-
vious findings demonstrating the result of miR-
21 knockdown, similar outcomes could be seen
following the knockdown of miR-21 in leukemic
stem cells.
Conclusions
Improving life quality and expectancy following
diagnosis with leukemia has always been difficult
for oncologists, as the majority of chemothera-
peutic regimens have significant side effects and
limited efficacy. Hematopoietic stem cell trans-
plantation may be considered in the treatment of
leukemia, but is costly in developing countries and
may lead to serious graft-versus-host disease and
immunological rejection. Alternative approaches,
such as using antibodies or vaccines, are currently,
for the most part, experimental and in the early
stages of clinical use. The discovery that miR-21
is a key miRNA (oncomir) that is dysregulated 
in many cancers indicates an important role of
miRNAs in cancer. This finding starts a new era
of cancer investigations.
Determining how miR-21 is regulated and how
it regulates downstream target genes will be a pre-
requisite for rational design of cancer therapeutic
strategies. Modulation of miR-21 expression can
also be used as a diagnostic and prognostic marker
for cancer sufferers, leukemia patients in particular.
Previously, little knowledge about the role of
these small non-coding RNA molecules in the pa-
thogenesis of leukemia existed. With the discovery
of new miRNAs and new non-coding RNAs, fur-
ther studies are needed to define specific processes
and molecular interactions to improve leukemia
patient care. Therefore, a mixed strategy of con-
comitantly targeting oncogenes by using com-
bined RNA drugs may be a possibility.
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